SCHEMBL5886102

SCHEMBL5886102

C#CC(CC(=O)OCC)Nc1cccc(C#N)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDCD1 Q15116 1/20 0.45
CD274 Q9NZQ7 1/20 0.45
ALOX15 P16050 1/20 0.44
SETD7 Q8WTS6 1/20 0.44
ITGB3 P05106 1/20 0.42
ITGA2B P08514 1/20 0.42
RXFP1 Q9HBX9 1/20 0.41
CTSL P07711 1/20 0.41
CTSB P07858 1/20 0.41
CTSK P43235 1/20 0.41
MEN1 O00255 1/20 0.40
ALDH1A1 P00352 1/20 0.40
MAPT P10636 1/20 0.40
KMT2A Q03164 1/20 0.40
MCHR1 Q99705 1/20 0.40
RORC P51449 1/20 0.40
LMNA P02545 1/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL696336 0.76 ALDH1A1 (0.52) PDCD1CD274ALOX15SETD7RXFP1
SCHEMBL28069422 0.74 ALOX15 (0.50) PDCD1CD274ALOX15SETD7RXFP1
SCHEMBL11813065 0.73 SETD7 (0.52) PDCD1CD274ALOX15SETD7RXFP1
SCHEMBL7360595 0.73 PDCD1 (0.50) PDCD1CD274ALOX15FNTAFNTB
SCHEMBL5885573 0.72 MAPT (0.48) ALOX15CTSLCTSBCTSKMEN1
SCHEMBL6329440 0.72 PDCD1 (0.49) PDCD1CD274ALOX15SETD7FNTA
SCHEMBL9364693 0.71 GPR35 (0.58) PDCD1CD274ALOX15SETD7RXFP1
SCHEMBL7361595 0.71 PDCD1 (0.48) PDCD1CD274RXFP1FNTAFNTB
SCHEMBL23354683 0.70 PDCD1 (0.45) PDCD1CD274ALOX15SETD7RXFP1
SCHEMBL1659817 0.70 GSK3B (0.57) PDCD1CD274ALOX15SETD7MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7005437-B2 Substituted aryl and heteroaryl derivatives, the preparation thereof and the use therof as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA KG (DE) 2006-02-28 US disclosed
US-20030045712-A1 Substituted aryl and heteroaryl derivatives, the preparation thereof and the use therof as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA KG (DE) 2003-03-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030045712-A1 Substituted aryl and heteroaryl derivatives, the preparation thereof and the use therof as pharmaceutical compositions F2, F12, F3 PDCD1 3972/4885CD274 4018/4885ALOX15 439/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.